Of the 227 articles related to the tumor microenvironment after EGFR mutations in non-small cell lung cancer, 112 journals were covered (Table 3), Frontiers in Oncology published most papers (n=16, 14.3%), followed by Clinical Cancer Research (n=11, 9.8%), Lung Cancer (n=9, 8.0%), and Journal for Immunotherapy of Cancer (n=9, 8.0%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.